[DOI] [PMC free article] [PubMed] [Google Scholar] 91.Li Y., Yao J., Han C., Yang J., Chaudhry M.T., Wang S., Liu H., Yin Y
One notable study, known as the STEP (Semaglutide Treatment Effect in People with Obesity) trial, involved over 4,500 participants with obesity or overweight and comorbidities
Additionally, it exhibit anti-proliferative properties that may contribute to lowering the risk of lung, colon, and breast cancers.[1] [2] The table below shows the health effects and description
[12] Ren K, Dubner R
They stimulate insulin release when blood sugar is high and reduce glucagon (a hormone that raises blood sugar)
Semaglutide, a medication initially developed to treat Type 2 Diabetes, has shown promising results in weight loss studies